Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 30
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Cabaletta Bio Inc
CABA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.51
-0.075
-4.73%
Dern. MÀJ: Oct 30, 4:12 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Cabaletta Bio Financials
Cabaletta Bio (CABA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 53.42 percent increase over losses of $(0.73) per share from
Benzinga Newsdesk
PRO
Cabaletta Bio Q1 EPS $(0.39), Inline
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.39) per share which met the analyst consensus estimate. This is a 45.07 percent increase over losses of $(0.71) per share from the same period last year.
Benzinga Newsdesk
PRO
Cabaletta Bio Q4 EPS $(0.40) Beats $(0.47) Estimate
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 13.98 percent. This is a 38.46 percent increase over losses of $(0.65) per share from the
Benzinga Newsdesk
PRO
Cabaletta Bio Q3 EPS $(0.44) Beats $(0.45) Estimate; Cash, Cash Equivalents And Short-Term Investments Of $159.9M Provides Cash Runway Into 2H 2026
Benzinga Newsdesk
PRO
Cabaletta Bio Q2 EPS $(0.73) Misses $(0.61) Estimate
Benzinga Newsdesk
PRO
Cabaletta Bio Q4 2024 GAAP EPS $(0.65) Misses $(0.63) Estimate, Operational Runway Into 1H26 With Cash And Cash Equivalents Of $164M As Of December 31, 2024
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.63) by 3.17 percent. This is a 41.3 percent decrease over losses of $(0.46) per share from the
Benzinga Newsdesk
